Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human GEN1106 in solid tumors
jRCT2031260042Phase 1Recruiting
- Sponsor
- Genmab
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of GEN1106 in transitional cell carcinoma (TCC) and Nonhematologic neoplasms, sponsored by Genmab. Primary endpoints: Dose-limiting toxicities in Part 1, Safety (AEs and SAEs) in Part 1 and 2 more. Started Apr 2026; status: recruiting.
02
Drugs
GEN1106
03
Conditions
transitional cell carcinoma (TCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031260042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260042.